Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.

Saved in:
Bibliographic Details
Title: Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.
Authors: Mitchell J; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Camacho N; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Shea P; Institute for Genomic Medicine, Columbia University, New York, New York, USA., Stopsack KH; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA., Joseph V; Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, New York, USA., Burren O; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Dhindsa R; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Nag A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Berchuck JE; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., O'Neill A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Abbasi A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Zoghbi AW; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA., Alegre-Díaz J; Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, Ciudad de México, Mexico., Kuri-Morales P; Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, Ciudad de México, Mexico.; Instituto Tecnológico y de Estudios Superiores de Monterrey, Tecnológico, Monterrey, Nuevo León, Mexico., Berumen J; Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, Ciudad de México, Mexico., Tapia-Conyer R; Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Coyoacán, Ciudad de México, Mexico., Emberson J; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Torres JM; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Collins R; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Wang Q; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts, USA., Goldstein D; Institute for Genomic Medicine, Columbia University, New York, New York, USA., Matakidou A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Haefliger C; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Anderson-Dring L; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., March R; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Jobanputra V; Institute for Genomic Medicine, Columbia University, New York, New York, USA., Dougherty B; Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA., Carss K; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Petrovski S; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Kantoff PW; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Convergent Therapeutics, Cambridge, Massachusetts, USA., Offit K; Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, New York, USA., Mucci LA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.; American Cancer Society, Boston, Massachusetts, USA., Pomerantz M; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Fabre MA; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.
Source: MedRxiv : the preprint server for health sciences [medRxiv] 2024 May 10. Date of Electronic Publication: 2024 May 10.
Publication Type: Preprint; Journal Article
Journal Info: Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
DOI:10.1101/2024.05.10.24307164